Clinical Trials on Constipation - Functional in South Africa

Total 176 results

Sucampo Pharma Americas, LLC
Sucampo AG

Completed

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

Constipation - Functional

United States
Anji Pharma
Covance

Completed

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation

China, United States
Allergan
Ironwood Pharmaceuticals, Inc.

Completed

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Functional Constipation

United States
University of Johannesburg

Completed

The Efficacy of Individualised Homeopathic Treatment on Constipation

Constipation

South Africa
Prof Mags Beksinska

Completed

Functional Performance and Acceptability Study of Synthetic Nitrile, and Latex Graphene, Compared to Standard Latex Male Condom

Functional Performance

South Africa
AbbVie
Ironwood Pharmaceuticals, Inc.

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Functional Constipation

United States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
Sucampo Pharma Americas, LLC
Takeda

Completed

Lubiprostone for Children With Constipation

Constipation - Functional

United States, United Kingdom, Netherlands, Poland, Belgium, France, Canada
Sucampo Pharma Americas, LLC
Sucampo AG

Completed

Lubiprostone in Children With Functional Constipation

Constipation - Functional

United States, United Kingdom, Canada, Netherlands, Poland, Belgium, France
AbbVie
Ironwood Pharmaceuticals, Inc.

Recruiting

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Functional Constipation (FC) | Chronic Idiopathic Constipation (CIC)

United States, United Kingdom, Bulgaria, Netherlands
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

Functional Constipation in Children Ages 6-17 Years

United States, Canada
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
University of Stellenbosch
Nestlè Nutrition Institute Africa; National Research Foundation (NRF) (RSA)

Completed

Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome

Irritable Bowel Syndrome

South Africa
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada
Ardelyx

Enrolling by invitation

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Ardelyx

Completed

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.

Completed

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States, Canada
Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Bausch Health Americas, Inc.

Completed

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS)

Irritable Bowel Syndrome Characterized by Constipation

United States
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
Bausch Health Americas, Inc.

Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
University of Cape Town
Stanford University

Recruiting

Point-of-care Ultrasound Abnormalities in Early Onset Preeclampsia

Preeclampsia | Pulmonary Edema | Cardiac Function

South Africa
Ferring Pharmaceuticals

Completed

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States, Belgium, Canada, Czech Republic, Hungary, Poland, Slovakia, South Africa, Sweden, United Kingdom
Bausch Health Americas, Inc.

Completed

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)

Non-Constipation Irritable Bowel Syndrome

United States
Mallinckrodt
Takeda; Sucampo Pharma Americas, LLC; Sucampo AG

Completed

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Ferring Pharmaceuticals

Terminated

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Sweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
Amsterdam UMC, location VUmc
Radboud University Medical Center; University Medical Center Groningen; UMC Utrecht and other collaborators

Recruiting

Prevention of Opioid-induced Constipation in Patients With Advanced Cancer (OMAMA)

Constipation, Opioid-Induced

Netherlands
Procter and Gamble

Terminated

Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation

Chronic Constipation

United States, Canada
Sheffield Children's NHS Foundation Trust

Completed

Ultrafast MRI Imaging to Exclude Constipation (FIESTA)

Constipation

United Kingdom
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Ferring Pharmaceuticals

Terminated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Israel, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa
Shionogi

Completed

Long Term Safety of Naldemedine

Opioid-induced Constipation

United States, Australia, Austria, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Poland, South Africa, Spain, Sweden, United Kingdom
Albireo

Completed

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation (ACCESS)

Constipation | Chronic Constipation

United States
Unity Health Toronto

Completed

Transfusion Requirements in Cardiac Surgery III (TRICS-III)

Disorder; Heart, Functional, Postoperative, Cardiac Surgery

Canada, Spain, United States, Israel, Australia, New Zealand, Denmark, Colombia, Egypt, Germany, Singapore, Switzerland, China, Brazil, Greece, India, Malaysia, Romania, South Africa
AstraZeneca

Completed

Longitudinal Study of Patients With Opioid-Induced Constipation

Patients With Opioid Induced Constipation

Canada, United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
Ironwood Pharmaceuticals, Inc.

Completed

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Chronic Constipation

United States
Cardiac Dimensions Pty Ltd

Terminated

An Initial Evaluation of the Carillon Mitral Contour System for Treatment of Atrial Function Mitral Regurgitation (AFIRE)

Atrial Fibrillation | Functional Mitral Regurgitation | Atrial Functional Mitral Regurgitation

Australia, Greece
Braintree Laboratories

Completed

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Constipation | Chronic Idiopathic Constipation | CIC

United States

Clinical Trials on Constipation - Functional in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations